These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Effect of combination of anticytokine preparations anaferon and artrofoon on immune inflammation in rheumatoid arthritis. Petrov VI; Babaeva AR; Solodenkova KS; Cherevkova EV; Zabolotneva YA; Kachanova MV; Sergeeva SA Bull Exp Biol Med; 2009 Sep; 148(3):489-92. PubMed ID: 20396720 [TBL] [Abstract][Full Text] [Related]
6. Clinical efficiency and tolerability of artrofoon in patients with rheumatoid arthritis associated with osteopenic syndrome. Peshekhonova LK; Chernov YN; Barsukova NA; Peshekhonov DV Bull Exp Biol Med; 2009 Sep; 148(3):468-9. PubMed ID: 20396714 [TBL] [Abstract][Full Text] [Related]
7. Adalimumab, a fully human anti tumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis). Furst DE; Schiff MH; Fleischmann RM; Strand V; Birbara CA; Compagnone D; Fischkoff SA; Chartash EK J Rheumatol; 2003 Dec; 30(12):2563-71. PubMed ID: 14719195 [TBL] [Abstract][Full Text] [Related]
8. Canadian variation by province in rheumatoid arthritis initiating anti-tumor necrosis factor therapy: results from the optimization of adalimumab trial. Pease C; Pope JE; Thorne C; Haraoui BP; Truong D; Bombardier C; Widdifield J; Psaradellis E; Sampalis JS; Bonner A J Rheumatol; 2010 Dec; 37(12):2469-74. PubMed ID: 20843910 [TBL] [Abstract][Full Text] [Related]
9. Tumor necrosis factor-alpha blockade and the risk of vasculitis. Guillevin L; Mouthon L J Rheumatol; 2004 Oct; 31(10):1885-7. PubMed ID: 15468348 [No Abstract] [Full Text] [Related]
10. Efficiency and tolerability of artrofoon (ultralow doses and antibodies to TNF-alpha) in osteoarthrosis. Alikhanov BA; Pavlenko AY Bull Exp Biol Med; 2009 Sep; 148(3):470-3. PubMed ID: 20396715 [TBL] [Abstract][Full Text] [Related]
11. [Infliximab for therapy of rheumatoid arthritis]. Amano K Nihon Rinsho; 2005 Jan; 63 Suppl 1():517-20. PubMed ID: 15799410 [No Abstract] [Full Text] [Related]
12. TNF-alpha inhibition: the need for a tumor necrosis factor thermostat. O'Dell JR Mayo Clin Proc; 2001 Jun; 76(6):573-5. PubMed ID: 11393494 [No Abstract] [Full Text] [Related]
13. [Guidelines for usage of biological agents for treatment of rheumatoid arthritis]. Takeuchi T Nihon Rinsho; 2005 Jan; 63 Suppl 1():444-7. PubMed ID: 15799396 [No Abstract] [Full Text] [Related]
14. Experimental and clinical study of the effect of artrofoon on proinflammatory cytokine production. Kachanova MV; Sherstoboyev EY; Babayeva AR; Tcherevkova EV; Dugina JL; Kislitsyna OS; Epstein OI; Sergeeva SA Bull Exp Biol Med; 2008 Jan; 145(1):58-61. PubMed ID: 19024003 [TBL] [Abstract][Full Text] [Related]
15. Atypical cutaneous tuberculosis in a patient with rheumatoid arthritis treated with infliximab. Asano Y; Kano Y; Shiohara T Acta Derm Venereol; 2008; 88(2):183-4. PubMed ID: 18311458 [No Abstract] [Full Text] [Related]
16. Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. Lipsky PE; van der Heijde DM; St Clair EW; Furst DE; Breedveld FC; Kalden JR; Smolen JS; Weisman M; Emery P; Feldmann M; Harriman GR; Maini RN; N Engl J Med; 2000 Nov; 343(22):1594-602. PubMed ID: 11096166 [TBL] [Abstract][Full Text] [Related]